Gilead Sciences (NASDAQ:GILD) announced Friday that its antibody-drug conjugate Trodelvy reached the main goal compared to ...

After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

The stock's fall snapped a four-day winning streak.

Shares of Gilead Sciences Inc. advanced 3.57% to $106.16 Monday, on what proved to be an all-around great trading session for ...

HSV-1 infection may be linked to the risk for Alzheimer’s disease, but antiviral treatment may be protective, a large ...